Author: healthylife7

Neurocrine Biosciences has initiated a Phase 1 clinical trial to test the safety and tolerability of NBIP-‘1968, a novel triple agonist drug targeting GLP-1, GIP, and glucagon receptors for obesity treatment. This investigational drug aims to address obesity by engaging three metabolic mechanisms to regulate appetite, energy balance, and glycemic control. The study will involve…

Read More